Download PDF
Thromb Haemost 2007; 97(06): 1031-1036
DOI: 10.1160/TH06-09-0494
Cellular Proteolysis and Oncology
Schattauer GmbH

Thalidomide and thrombosis

A meta-analysis
Ramzi N. El Accaoui   *
,
Wael A. Shamseddeen   *
,
Ali T. Taher
1   American University of Beirut Medical Center, Beirut, Lebanon
› Author Affiliations
Further Information

Publication History

Received: 03 September 2006

Accepted after resubmission 20 March 2007

Publication Date:
27 November 2017 (online)

    Permissions and Reprints

Summary

With the increase in the number of reports and trials on the use of thalidomide as a part of the treatment of different medical conditions, particularly multiple myeloma (MM), it was observed that this drug might be associated with an increase in the risk of venous thromboembolic (VTE) events. It was the objective of this study to assess this risk, to check whether it might be affected by the concomitant administration of other medications, specifically dexamethasone, and to study the effect of anticoagulation and anti-platelet medications. A literature search for articles describing the use of thalidomide and the resultant VTE events was performed, and 50 articles were reviewed. A sample consisting of 3,322 patients resembling the above-mentioned studies was designed, and multivariate logistic regression was conducted.While thalidomide, dexamethasone and their combination were found to significantly increase the risk of VTE events among MM patients by 2.6, 2.8 and eight times, respectively, “adequate” anticoagulation significantly reduced the risk. In conclusion, patients receiving thalidomide should be carefully monitored for thromboembolic events,and those receiving concomitantly dexamethasone or other chemotherapy should be followed even more closely. Administering prophylactic doses of low-molecular-weight heparin or warfarin with therapeutic International Normalized Ratio reduces the risk of thromboembolic events among MM patients.

Keywords

Multiple myeloma - thalidomide - thrombosis

* These authors contributed equally.


 

  • References

  • 1 McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; 2: 1358.
    CrossrefPubMedGoogle Scholar
  • 2 Clark TE, Edom N, Larson J. et al Thalomide capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing. Drug Saf 2001; 24: 87-117.
    CrossrefPubMedGoogle Scholar
  • 3 Moreira AL, Sampaio EP, Zmuidzinas A. et al Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680.
    CrossrefPubMedGoogle Scholar
  • 4 Kruse FE, Joussen AM, Rohrschneider K. et al Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol 1998; 236: 461-466.
    CrossrefPubMedGoogle Scholar
  • 5 Abdelkefi A, Torjman L, Romdhane NB. et al Firstline thalidomide-dexamethasone therapy in preparation for autologous stem cell transplantation in young patients (< 61 years) with symptomatic multiple myeloma. Bone Marrow Transplant 2005; 36: 193-198.
    CrossrefPubMedGoogle Scholar
  • 6 Agrawal NR, Hussein MA, Elson P. et al Pegylated doxorubicin (D), vincristine (V), reduced frequency dexamethasone (D) and thalidomide(T) (DVd-T) in newly diagnosed (Nmm) and relapsed/refractory (Rmm) multiple myeloma patients Blood. 2003; 102 Abstract 831.
    PubMedGoogle Scholar
  • 7 Anagnostopoulos A, Weber D, Rankin K. et al Thalidomide and dexamethasone for resistant multiple myeloma. Br J Haematol 2003; 121: 768-771.
    CrossrefPubMedGoogle Scholar
  • 8 Barlogie B, Desikan R, Eddlemon P. et al Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: Identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001; 98: 492-494.
    CrossrefPubMedGoogle Scholar
  • 9 Baz R, Pearce G, McGowan B. et al Aspirin increases the survival free from death or deep vein thrombosis of liposomal doxorubicin, vincristine, decreased frequency dexamethasone and thalidomide (DVd-T) treatment of multiple myeloma. International Multiple Myeloma Workshop. 10th International Myeloma Workshop; Sidney, Australia: April 10–14, 2005, Abstract PO.719.
    Google Scholar
  • 10 Bowcock SJ, Rassam SMB, Ward SM. et al Thromboembolism in patients on thalidomide for myeloma. Hematology 2002; 7: 51-53.
    CrossrefPubMedGoogle Scholar
  • 11 Camba L, Peccatori J, Pescarollo A. et al Thalidomide and thrombosis in patients with multiple myeloma. Haematologica 2001; 86: 1108-1109.
    PubMedGoogle Scholar
  • 12 Cavo M, Zamagni E, Tosi P. et al First-line therapy with thalidomide and dexamethasone in preparation for autologous stem cell transplantation for multiple myeloma. Haematologica 2004; 89: 826-831.
    PubMedGoogle Scholar
  • 13 Corso A, Lorenzi A, Terulla V. et al Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with Thalidomide and Dexamethasone. Ann Hematology 2004; 83: 588-591.
    PubMedGoogle Scholar
  • 14 Dimopoulos MA, Hamilos G, Zomas A. et al Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematology J 2004; 5: 112-117.
    PubMedGoogle Scholar
  • 15 Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM. et al The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004; 18: 856-863.
    CrossrefPubMedGoogle Scholar
  • 16 Hassoun H, Reich L, Klimek VM. et al Doxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myeloma. Br J Haematol 2005; 132: 155-161.
    PubMedGoogle Scholar
  • 17 Kropff MH, Lang N, Bisping G. et al Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003; 122: 607-616.
    CrossrefPubMedGoogle Scholar
  • 18 Minnema MC, Breitkreutz I, Auwerda JJA. et al Prevention of venous thromboembolism with low molecular- weight heparin in patients with multiple myeloma treated with thalidomide and chemotherapy. Leukemia 2004; 18: 2044-2046.
    CrossrefPubMedGoogle Scholar
  • 19 Minnema MC, Fijnheer R, De Groot PG. et al Extremely high levels of von Willebrand factor antigen and of procoagulant factor VIII found in multiple myeloma patients are associated with activity status but not with thalidomide treatment. J Thromb Haemost 2003; 1: 445-449.
    CrossrefPubMedGoogle Scholar
  • 20 Moehler T, Hillengass J, Gerull S. et al Thalidomide (T) and CED chemotherapy followed by stem cell transplantation for poor prognosis multiple myeloma. Blood 2003; 102 Abstract 2652.
    PubMedGoogle Scholar
  • 21 Neben K, Moehler T, Benner A. et al Dose-dependent effect of thalidomide on overall survival in relapsed multiple myeloma. Clin Cancer Res 2002; 8: 3377-3382.
    PubMedGoogle Scholar
  • 22 Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med 2001; 344: 1951-1952.
    CrossrefPubMedGoogle Scholar
  • 23 Rajkumar SV, Blood E, Vesole DH. et al A randomized phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): A trial coordinated by the Easter Cooperative Oncology Group. Proc Am Soc Clin Oncol 2004; 23: 558 Abstract 6508.
    PubMedGoogle Scholar
  • 24 Rajkumar SV, Gertz MA, Lacy MQ. et al Thalidomide as initial therapy for early-stage myeloma. Leukemia 2003; 17: 775-779.
    CrossrefPubMedGoogle Scholar
  • 25 Rajkumar SV, Hayman S, Gertz M. et al Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma. J Clin Oncol 2002; 20: 4319-4323.
    CrossrefPubMedGoogle Scholar
  • 26 Rus C, Bazzan M, Palumbo A. et al Thalidomide in front line treatment in multiple myeloma: serious risk of venous thromboembolism and evidence for thromboprophylaxis. J Thromb Haemost 2004; 2: 2063-2065.
    CrossrefPubMedGoogle Scholar
  • 27 Schey SA, Cavenagh J, Johnson R. et al An UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment. Leukemia Res 2003; 27: 909-914.
    CrossrefPubMedGoogle Scholar
  • 28 Tso E, Baz R, Marchant K. et al Aspirin (ASA) prophylaxis during treatment (TTT) of multiple myeloma (MM) using liposomal doxorubicin, vincristine, decreased- frequency dexamethasone and thalidomide (DVd-T) decreases post-treatment thrombosis (DVT). Proc Am Soc Clin Oncol 2003; 22: 584 (Abstract 2349).
    PubMedGoogle Scholar
  • 29 Valdre L, Cini M, Legnani C. et al Venous thromboembolic complications in patients with multiple myeloma treated with thalidomide: Prophylactic effect of fixed dose warfarin. Pathophysiology Haemost Thromb 2003; 33 (Suppl. 01) 70-71.
    PubMedGoogle Scholar
  • 30 Weber D, Rankin K, Gavino M. et al Thalidomide alone or with dexamethasone for previously untreated multiple myeloma. J Clin Oncol 2003; 21: 16-19.
    CrossrefPubMedGoogle Scholar
  • 31 Zangari M, Anaissie E, Barlogie B. et al Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving Thalidomide and chemotherapy. Blood 2001; 98: 1614-1615.
    CrossrefPubMedGoogle Scholar
  • 32 Zangari M, Barlogie B, Lee CK. et al Protective effect of Velcade® on Thalidomide associated deep vein thrombosis (DVT). American Society of Hematology. 46th Annual Meeting, San Diego, California, USA: December 4–7, 2004, Abstract 4914.
    Google Scholar
  • 33 Zangari M, Barlogie B, Thertulien R. et al Effect of anticoagulation on development and recurrence of deep vein thrombosis (DVT) in multiple myeloma patients treated with chemotherapy and thalidomide (total therapy II). Hematology J 2003; 4 (Suppl. 01) S248 (Abstract 358).
    PubMedGoogle Scholar
  • 34 Zangari M, Saghafifar F, Anaissie E. et al Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications. Blood Coagul Fibrinolysis 2002; 13: 187-192.
    CrossrefPubMedGoogle Scholar
  • 35 Zangari M, Siegel E, Barlogie B. et al Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: Implications for therapy. Blood 2002; 100: 1168-1171.
    CrossrefPubMedGoogle Scholar
  • 36 Zervas K, Dimopoulos MA, Hatzicharissi E. et al Primary treatment of multiple myeloma with thalidomide, vincristine, liposomal doxorubicin and dexamethasone (T-VAD doxil): A phase II multicenter study. Ann Oncology 2004; 15: 134-138.
    CrossrefPubMedGoogle Scholar
  • 37 Urbauer E, Kaufmann H, Nosslinger T. et al Thromboembolic events during treatment with thalidomide. Blood 2002; 99: 4247-4248.
    CrossrefPubMedGoogle Scholar
  • 38 Steurer M, Sudmeier I, Stauder R. et al Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin- alpha. Br J Haematol 2003; 121: 101-103.
    CrossrefPubMedGoogle Scholar
  • 39 Dahut WL, Gulley JL, Arlen PM. et al Randomized phase II trial of docetaxel plus thalidomide in androgen- independent prostate cancer. J Clin Oncol 2004; 22: 2532-2539.
    CrossrefPubMedGoogle Scholar
  • 40 Daliani D, Dieringer P, Papandreou CN. et al A tolerance and efficacy study of thalidomide, paclitaxel, and estramustine for patients with chemotherapy refractory androgen independent prostate cancer. Cancer Investigation 2003; Abstract 48.
    PubMedGoogle Scholar
  • 41 Horne MK, Figg WD, Arlen P. et al Increased frequency of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. Pharmacotherapy 2003; 23: 315-318.
    CrossrefPubMedGoogle Scholar
  • 42 Salimichokami M. Combining angiogenesis inhibitors with cytotoxic chemotherapy enhances PSA response in hormone-refractory prostate cancer (HRPC): A randomized study of weekly docetaxel alone or in combination with Thalidomide. Proc Am Soc Clin Oncol 2003; 22: 429 Abstract 1725.
    PubMedGoogle Scholar
  • 43 Cavaliere R, Farace E, Wen P. et al Thalidomide-associated thromboembolic events in patients with highgrade gliomas. Society of Neuro-Oncology, 9 th Annual Meeting. Toronto, Canada: November 18–21, 2004, Abstract TA-11.
    Google Scholar
  • 44 Fine HA, Maher EA, Wen PY. et al Phase II trial of Thalidomide and BCNU in recurrent highgrade gliomas. Proc Am Soc Clin Oncol 2001; 20: 55 a, Abstract 218.
    PubMedGoogle Scholar
  • 45 Desai AA, Vogelzang NJ, Rini BI. et al A high rate of venous thromboembolism in a multiinstitutional phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil and daily thalidomide in patients with metastatic renal cell carcinoma. Cancer 2002; 95: 1629-1636.
    CrossrefPubMedGoogle Scholar
  • 46 Escudier B, Lassau N, Couanet D. et al Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002; 13: 1029-1035.
    CrossrefPubMedGoogle Scholar
  • 47 Anderson KC. Advances in disease biology: therapeutic implications. Semin Hematol 2001; 38 (Suppl. 03) 6-10.
    PubMedGoogle Scholar
  • 48 Kuenen BC, Rosen L, Smit EF. et al Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in patients with solid tumors. J Clin Oncol 2002; 20: 1657-1667.
    CrossrefPubMedGoogle Scholar
  • 49 Lum H, Roebuck KA. Oxidant stress and endothelial cell dysfunction. Am J Physiol Cell Physiol 2001; 280: 719-724.
    CrossrefPubMedGoogle Scholar
  • 50 Arnman V, Stemme S, Rymo L. et al Interferon- γ modulates the fibrinolytic response in cultured human endothelial cells. Thromb Res 1995; 77: 431-440.
    CrossrefPubMedGoogle Scholar
  • 51 Easterbrook PJ, Berlin JA, Gopalan R. et al Publication bias in clinical research. Lancet 1991; 337: 867-872.
    CrossrefPubMedGoogle Scholar